Sarepta (SRPT) Wins Key PTO Decision on Composition of Matter Patents - Oppenheimer

September 20, 2016 1:18 PM EDT
Get Alerts SRPT Hot Sheet
Price: $61.49 +0.84%

Rating Summary:
    16 Buy, 8 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 9 | New: 77
Trade SRPT Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Oppenheimer analyst Michelle Gilson notes US Patent and Trademark Office ruled in favor of Sarepta (NASDAQ: SRPT) for Patents 7,960,541 and 7,807,816 in its patent interference proceeding (interference number 106,008).

Gilson notes these cover composition of matter for eteplirsen, giving the Sarepta freedom to operate and IP in commercialization of eteplirsen in the US. Additionally, it complicates enforcement of last year's "method of use" ruling in favor of BioMarin (note here). The decision is subject to appeal.

The firm Outperform price target of $76.00

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $48.94 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Litigation, Momentum Movers, Trader Talk

Add Your Comment